Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 406,463,200
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,034 M
  • EBITDA $ 17,420 M
  • 60-Month Beta 0.36
  • Price/Sales 7.21
  • Price/Cash Flow 15.40
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 24.84% (+2.06%)
  • Historical Volatility 20.02%
  • IV Percentile 46%
  • IV Rank 21.31%
  • IV High 51.27% on 04/08/25
  • IV Low 17.68% on 02/19/25
  • Expected Move (DTE 6) 3.82 (1.66%)
  • Put/Call Vol Ratio 1.02
  • Today's Volume 9,065
  • Volume Avg (30-Day) 10,755
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 272,737
  • Open Int (30-Day) 299,622
  • Expected Range 226.16 to 233.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 3.37
  • Number of Estimates 8
  • High Estimate 3.52
  • Low Estimate 3.30
  • Prior Year 2.16
  • Growth Rate Est. (year over year) +56.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.23 +4.43%
on 12/09/25
230.94 -0.42%
on 12/04/25
+2.32 (+1.02%)
since 11/26/25
3-Month
211.69 +8.64%
on 11/03/25
244.81 -6.06%
on 10/01/25
+9.37 (+4.25%)
since 09/26/25
52-Week
164.39 +39.90%
on 04/09/25
244.81 -6.06%
on 10/01/25
+50.78 (+28.34%)
since 12/26/24

Most Recent Stories

More News
2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

$SPX : 6,929.94 (-0.03%)
JNJ : 207.63 (-0.07%)
ABBV : 229.98 (+0.04%)
3 Dividend Growth Stocks Analysts Are Upgrading for 2026

United Parcel Service, PepsiCo, and AbbVie are healthy dividend payers whose analyst trends support an outlook for price strength in 2026.

UPS : 100.54 (-0.12%)
PEP : 143.78 (+0.03%)
ABBV : 229.98 (+0.04%)
3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

JNJ : 207.63 (-0.07%)
ABBV : 229.98 (+0.04%)
NUE : 166.35 (+0.52%)
AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something

An intriguing quant signal combined with shifting sentiment in the derivatives market opens the possibility toward a bullish trade for ABBV stock.

ABBV : 229.98 (+0.04%)
Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul

AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026

IXJ : 98.19 (+0.10%)
ABBV : 229.98 (+0.04%)
AMZN : 232.52 (+0.06%)
MCD : 310.68 (-0.85%)
WMT : 111.74 (+0.12%)
2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore

2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore

NVDA : 190.53 (+1.02%)
MRK : 106.78 (+0.31%)
ABBV : 229.98 (+0.04%)
3 Dividend Aristocrats on the Edge of a Big Move

Discover three high-yield Dividend Aristocrats showing strong fundamentals and analyst support as they set up for a potential breakout.

SYY : 74.23 (-0.03%)
PG : 144.74 (+0.17%)
ABBV : 229.98 (+0.04%)
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

NORTH CHICAGO, Ill. , Dec. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances...

ABBV : 229.98 (+0.04%)
3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

KO : 69.87 (-0.34%)
JNJ : 207.63 (-0.07%)
ABBV : 229.98 (+0.04%)
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI ® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s...

ABBV : 229.98 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 232.76
2nd Resistance Point 231.68
1st Resistance Point 230.83
Last Price 229.98
1st Support Level 228.90
2nd Support Level 227.83
3rd Support Level 226.98

See More

52-Week High 244.81
Last Price 229.98
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar